Log In

 
Biocon Limited
 

27/04/2017 9:45PM Document

Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; Board of Directors Recommends 2:1 Bonus Shares

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, announced today its consolidated financial results for the fourth quarter and full year FY17.

16/02/2017 7:25PM

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan’s Biologics License Application (BLA) for MYL-1401H, a ...

25/01/2017 8:34AM

Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, announced today that the Ministry of Health (MoH), Malaysia, has awarded a three-year contract, to its subsidiary, Biocon ...

24/01/2017 10:00PM Document

Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, announced today its consolidated financial results for the third quarter ended on December 31, 2016. Commenting on the ...

11/01/2017 6:40PM

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) and Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan’s biologics license application (BLA) for ...

27/12/2016 12:52PM

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the results of the HERITAGE study have been published in the Journal of the American Medical Association (JAMA). Study ...

12/11/2016 10:00AM

Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India

Biocon Ltd., Asia's premier biopharmaceuticals enterprise and the largest Indian insulins company, has collaborated with healthcare specialists for a month long patient centric support program to enable nationwide ...

08/11/2016 7:04PM

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

Potential to be First Submission of a Proposed Biosimilar Trastuzumab in the U.S. Marks First U.S. Regulatory Submission through the Mylan/Biocon Collaboration and Important Step in Expanding Access to Biosimilars ...

First<1234>Last